title: TDP-43 aggregation in neurodegeneration: are stress granules the key?
abstract: The RNA-binding protein TDP-43 is strongly linked to neurodegeneration. Not only are mutations in the gene encoding TDP-43 associated with ALS and FTLD, but this protein is also a major constituent of pathological intracellular inclusions in these diseases. Recent studies have significantly expanded our understanding of TDP-43 physiology. TDP-43 is now known to play important roles in neuronal RNA metabolism. It binds to and regulates the splicing and stability of numerous RNAs encoding proteins involved in neuronal development, synaptic function and neurodegeneration. Thus, a loss of these essential functions is an attractive hypothesis regarding the role of TDP-43 in neurodegeneration. Moreover, TDP-43 is an aggregation-prone protein and, given the role of toxic protein aggregates in neurodegeneration, a toxic gain-of-function mechanism is another rational hypothesis. Importantly, ALS related mutations modulate the propensity of TDP-43 to aggregate in cell culture. Several recent studies have documented that cytoplasmic TDP-43 aggregates co-localize with stress granule markers. Stress granules are cytoplasmic inclusions that repress translation of a subset of RNAs in times of cellular stress, and several proteins implicated in neurodegeneration (i.e. Ataxin-2 and SMN) interact with stress granules. Thus, understanding the interplay between TDP-43 aggregation, stress granules and the effect of ALS-associated TDP-43 mutations may be the key to understanding the role of TDP-43 in neurodegeneration. We propose two models of TDP-43 aggregate formation. The "independent model" stipulates that TDP-43 aggregation is independent of stress granule formation, in contrast to the "precursor model" which presents the idea that stress granule formation contributes to a TDP-43 aggregate "seed" and that chronic stress leads to concentration-dependent TDP-43 aggregation. This article is part of a Special Issue entitled: RNA-Binding Proteins.
authors.affiliation: Department of Neuroscience, The University of Texas Southwestern Medical Center at Dallas, USA.
authors.forename: Colleen M
authors.initials: CM
authors.lastname: Dewey
authors.forename: Basar
authors.initials: B
authors.lastname: Cenik
authors.forename: Chantelle F
authors.initials: CF
authors.lastname: Sephton
authors.forename: Brett A
authors.initials: BA
authors.lastname: Johnson
authors.forename: Joachim
authors.initials: J
authors.lastname: Herz
authors.forename: Gang
authors.initials: G
authors.lastname: Yu
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000235:genetics / Q000473:pathology; D000818:Animals; D003594:Cytoplasmic Granules / Q000473:pathology*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D057174:Frontotemporal Lobar Degeneration / Q000235:genetics / Q000473:pathology; D006801:Humans; D002479:Inclusion Bodies / Q000473:pathology; D019636:Neurodegenerative Diseases / Q000473:pathology*; D012313:RNA / Q000378:metabolism; D015398:Signal Transduction / Q000235:genetics; D057177:TDP-43 Proteinopathies / Q000473:pathology*
chemical_list: D004268:DNA-Binding Proteins; D012313:RNA